ALBIREO PHARMA, INC. Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2016 to Q3 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Albireo Pharma, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2016 to Q3 2022.
  • Albireo Pharma, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2022 was $3.55M, a 47.1% decline year-over-year.
  • Albireo Pharma, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2022 was $13.2M, a 25.7% decline year-over-year.
  • Albireo Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $15.9M, a 9% increase from 2020.
  • Albireo Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2020 was $14.6M, a 92.9% increase from 2019.
  • Albireo Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2019 was $7.58M, a 36.6% increase from 2018.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2022 $13.2M $3.55M -$3.16M -47.1% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-08
Q2 2022 $16.4M $3.62M +$112K +3.2% Apr 1, 2022 Jun 30, 2022 10-Q 2022-08-15
Q1 2022 $16.3M $3.42M +$359K +11.7% Jan 1, 2022 Mar 31, 2022 10-Q 2022-05-16
Q4 2021 $15.9M $2.66M -$1.88M -41.5% Oct 1, 2021 Dec 31, 2021 10-K 2022-03-01
Q3 2021 $17.8M $6.71M +$1.62M +31.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $16.2M $3.5M +$901K +34.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 $15.3M $3.06M +$681K +28.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 $14.6M $4.54M +$2.66M +142% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-01
Q3 2020 $12M $5.09M +$3.26M +179% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $8.69M $2.6M +$554K +27% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $8.14M $2.38M +$558K +30.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $7.58M $1.88M +$213K +12.8% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-25
Q3 2019 $7.37M $1.83M +$203K +12.5% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $7.16M $2.05M +$993K +94% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $6.17M $1.82M +$623K +51.9% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $5.55M $1.67M +$779K +87.7% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-02
Q3 2018 $4.77M $1.62M +$823K +103% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-06
Q2 2018 $3.94M $1.06M -$344K -24.6% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 $4.29M $1.2M +$588K +96.1% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $3.7M $888K Oct 1, 2017 Dec 31, 2017 10-K 2019-03-06
Q3 2017 $800K +$661K +476% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 $1.4M +$1.35M +2445% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 $612K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
Q3 2016 $139K Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-14
Q2 2016 $55K Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.